<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563200/" ref="ordinalpos=4024&amp;ncbi_uid=4616857&amp;link_uid=PMC3563200" image-link="/pmc/articles/PMC3563200/figure/fig03/" class="imagepopup">Figure 3.  From: Indoleamine 2,3-dioxygenase-1 (IDO1) enhances survival and invasiveness of endometrial stromal cells via the activation of JNK <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">JNK signaling pathway responsible for enhancement of the ESCs viability, proliferation and invasion by IDO1. IDO1-overexpressing and IDO1-deficiency ESCs were treated with JNK inhibitor (SP600125, 20 μM) or vehicle control (1‰ DMSO) for 24 h. Thereafter, MTT assay (A), apoptosis assay (B), BrdU assay (C) and Matrigel invasion assay (D) were applied to analyze the viability, apoptosis, proliferation and invasion of transfected ESCs, respectively. The columns represent the mean ± SD calculus of 8 different experiments. *P&lt;.05 vs. vector control transfected ESCs without SP600125; **P&lt;.01 vs. vector control transfected ESCs without SP600125; #P&lt;.05, IDO1-overexpressing ESCs with SP600125 vs. IDO1-overexpressing ESCs without SP600125; ##P&lt;.01, IDO1-overexpressing ESCs with SP600125 vs. IDO1-overexpressing ESCs without SP600125.</div></div>